作者: J. G. Kuhn , M. Gilbert , P. Wen , T. Cloughesy , J. Cooper
DOI: 10.1200/JCO.2009.27.15_SUPPL.2500
关键词: In patient 、 Medicine 、 Sorafenib 200 MG 、 Erlotinib 、 PK Parameters 、 Metabolite 、 Pharmacology 、 Maximum tolerated dose 、 Pharmacokinetics 、 Sorafenib
摘要: 2500 Background: The combination of sorafenib plus erlotinib was evaluated in patients with recurrent glioblastoma (GBM). In addition to defining the maximum tolerated dose (MTD), pharmacokinetics (PKs) for single agent and were determined. Methods: Adults GBM usual phase I inclusion/exclusion criteria eligible. No enzyme inducing anti-epileptic agents allowed. Starting doses 100mg PO QD 200 mg BID, respectively, 28 days (a cycle). For cycle 1 PKs, started on day followed 2 by sorafenib. Eight plasma samples collected over 24hrs 1, 15 28. Sorafenib its metabolite (N-oxide) analyzed HPLC OSI-420 LC/MS. PK parameters characterized standard non-compartmental methods. Results: MTD BID 100 QD. PKs (OSI) are displayed below. Conclusions: agreement wi...